Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses transplant decisions for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Currently, data from several studies support skipping or postponing stem cell transplantation (SCT) to the second complete remission (CR2) if the patient is MRD-negative. Prof. Nagler explains that the introduction of tyrosine kinase inhibitors (TKIs) and the use of measurable residual disease (MRD) monitoring have significantly improved the outcomes of patients with Ph+ ALL. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
